RECRUITING

A Phase 2 Study of MZE829 in Adults with APOL1 Kidney Disease

Description

This is purpose of this study is to evaluate the safety, tolerability, and effect on Albuminuria of MZE829 in Adults with APOL1 Kidney Disease

Conditions

Proteinuric Kidney Disease
Talk to us

Related Conditions:

Proteinuric Kidney Disease

Study Overview

On this page

Study Details

Study overview

This is purpose of this study is to evaluate the safety, tolerability, and effect on Albuminuria of MZE829 in Adults with APOL1 Kidney Disease

An Open-Label Phase 2 Study to Evaluate the Safety, Tolerability, and Effect on Albuminuria of MZE829 in Adults with Proteinuric Chronic Kidney Disease and the APOL1 High Risk Genotype

A Phase 2 Study of MZE829 in Adults with APOL1 Kidney Disease

Condition
Proteinuric Kidney Disease
Intervention / Treatment

-

Contacts and Locations

Huntsville

Apogee Clinical Research, Huntsville, Alabama, United States, 35805

Fairfield

Amicis Research Center, Fairfield, California, United States, 94534

Granada Hills

Amicis Research Center, Granada Hills, California, United States, 91344

Palmdale

Amicis Research Center, Palmdale, California, United States, 93551

Valencia

Amicis Research Center, Valencia, California, United States, 91355

Brandon

Clinical Research of Brandon, LLC, Brandon, Florida, United States, 33511

Fort Lauderdale

Florida Kidney Physicians, Fort Lauderdale, Florida, United States, 33316

Jacksonville

Florida Kidney Physicians, Jacksonville, Florida, United States, 32250

Miami Lakes

San Marcus Research Clinic, Inc., Miami Lakes, Florida, United States, 33014

Riverview

Florida Kidney Physicians, Riverview, Florida, United States, 33578

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * APOL1 high risk genotype of G1/G1, G2/G2, or G1/G2
  • * Chronic kidney disease with persistent albuminuria
  • * Organ or bone marrow transplantation
  • * History of cancer within past 2 years, excepted for treated non-melanoma skin cancer, stage 0 cervical cancer, or stage 1 prostate cancer
  • * Conditions that may alter drug absorption, e.g., history of bariatric surgery
  • * Type I diabetes
  • * Pregnant or currently nursing

Ages Eligible for Study

18 Years to 65 Years

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

Maze Therapeutics,

Medical Director, STUDY_DIRECTOR, Maze Therapeutics

Study Record Dates

2026-09